iBio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IBIO | OABI | INMB | BMEA | IMUX | VRXA | |
|---|---|---|---|---|---|---|
| Market cap | 58.08M | 693.51M | 49.40M | 98.33M | 108.47M | 161.20M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.5 | -16.3 | -4.1 | -1.4 | -3.3 | — |
| Price/book | 0.6 | 2.7 | 2.4 | 8.1 | 0.9 | -0.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +7.41% | +195.68% | +3.28% | −18.56% | −8.49% | −87.97% |
| Today | +3.70% | −0.42% | −5.82% | −4.23% | −2.93% | −9.52% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IBIO news ›iBio, Inc. Stock 12‑Month Price Target Raised to $5.6, Implies 509% Upside
TradingView iBio, Inc. Stock 12‑Month Price Target Raised to $5.6, Implies 509% Upside - According to estimates from 7 analysts, iBio, Inc. stock's average price target has risen from $5.53 to $5.6, with forecasts ranging from $4.2 to $7…
iBio, Inc. (IBIO) Presents at 2026 EASD Annual Meeting - Slideshow
2026-10-07. The following slide deck was published by iBio, Inc. The following slide deck was published by iBio, Inc. in conjunction with this event.
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody ... iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference SAN DIEGO, Sept.…
iBio initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of iBio (IBIO) with a Buy rating and $7 price target The firm believes IBIO-610’s activin E antibody “looks ... iBio initiated with a Buy at H.C. Wainwright H.C. Wainwright initiated coverage of iBio…
iBio Announces Proposed Public Offering
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the ... iBio Announces Proposed Public…
iBio Highlights Breakthrough Antibody Strategy for Obesity
An announcement from Ibio ( (IBIO) ) is now available. The most recent analyst rating on (IBIO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page. Spark’s…
iBio appoints Molly Carr as chief medical officer
iBio (IBIO) announced the appointment of Molly Carr as chief medical officer as the company advances its clinical-stage cardiometabolic pipeline... iBio appoints Molly Carr as chief medical officer iBio (IBIO) announced the appointment of…
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeut... iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as…
Ibio’s IBIO-610 reshapes weight loss composition
Human genetic and RNA-silencing studies suggest that reduced Activin E-ALK7 signaling is associated with favorable metabolic outcomes, supporting investigation of the pathway as a potential target for obesity treatment. Researchers from…
iBio, Inc. (NASDAQ:IBIO) Receives Average Recommendation of “Buy” from Analysts
Posted by Sarita Garza on Oct 3rd, 2026 View Our Latest Report on iBio NASDAQ:IBIO opened at $1.12 on Monday. The firm has a market cap of $72.35 million, a price-to-earnings ratio of -3.31 and a beta of 1.26. The company has a 50 day…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
markets.businessinsider.com4
-
theglobeandmail.com2
-
tradersunion.com2
-
seekingalpha.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.